Research and Publications
53
Research Trials
20
Peer-reviewed publications
16
Clinical Conditions
53
Research Trials
20
Peer-reviewed publications
16
Clinical Conditions
At CHEST 2025, held in Chicago, Illinois, Laurie Slovarp, PhD, CCC-SLP, professor at the University of Montana and certified speech pathologist, presented a poster on the development of a digital therapeutic designed to improve access to behavioral cough suppression therapy for patients with refractory chronic cough.
A large-scale trial examining the effect of azithromycin on the relationship between oesophageal function and cough as evaluated by Hyfe's cough monitoring technology in respiratory disease is feasible and acceptable to patients.
This study used Hyfe's wearable cough monitor during a 7-day run in, 28-day treatment, and 14-day follow-up period in patients with chronic bronchitis.
Periods of intense coughing (termed bouts, epochs or bursts) are particularly problematic for some coughers and may not be reflected by simply counting the number of coughs per day. This study explored how varying the definition of bouts yield different impressions of cough severity.
The world’s first DTx for Refractory/Unexplained Chronic Cough (RCC/UCC). What it is? Digitally delivered behavioral cough suppression therapy (BCST), designed for high engagement to promote strong adherence. It includes continuous, passive cough monitoring and biofeedback loop enabling tailored personalization.
A 7-day monitoring duration provides a robust, standardized timeframe for assessing cough frequency in clinical studies, offering a significant improvement over the traditional 24-hour period. This duration captures inter- and intra-individual cough variability.
This analysis of cough events demonstrated that the Hyfe CoughMonitor smartwatch, compared to a human listener, accurately detects coughs, with high sensitivity and a low false positive rate. Future studies should focus on its potential role in the management of patients with cough in clinical practice.
The article presents a dataset of 733,756 cough sounds from 2,143 patients across 7 countries, accompanied by accurate demographic, clinical, and microbiological diagnostic annotations. It was collected using an early version of Hyfe’s research application, specifically designed to capture cough audio.
This is an exploratory, single-blind, nasal saline-controlled study involving 12 patients with refractory chronic cough, designed to examine the cough suppression efficacy of alkaline salts, monitored objectively with the previous version of the Hyfe CoughMonitor Suite.
A single-blinded study in 12 chronic cough patients evaluated the cough-suppression efficacy of nasally delivered SC001 (pH 8 or 9) versus saline. Using Hyfe CoughMonitor, patients were monitored over three weeks. Results suggest alkaline (pH 9) SC001 aerosol shows promise for refractory chronic cough treatment.
A 30-day study of 12 chronic cough patients found no correlation between daily cough counts (median: 93/day) measured by the Hyfe CoughMonitor and symptom severity assessed via the Cough VAS. Further research is needed to identify better endpoints for evaluating chronic cough treatments.
Coughing frequencies vary significantly between and within individuals, for those with a cough frequency of >5 coughs/h. One 24-hour measurement of cough does not reliably reflect long-term trends in up to half of those with persistent cough. This work provides methodological direction for subsequent definitive studies
The Hyfe Cough Monitor System accurately monitors coughing in problematic coughers as they go about their usual daily activities. The ability to continually and passively monitor cough has the potential to improve patient care, cough research and drug development.
This pilot work clarifies a methodology for quantifying this phenomenon and provides preliminary evidence that non-user coughs have a negligible effect on the cough estimates of the Hyfe Cough Monitor Watch in real-world settings.
An earlier version of Hyfe’s cough monitoring technology was used to monitor cough for 6 months in this study with patients with pulmonary tuberculosis. Community-based continuous cough monitoring for pulmonary tuberculosis is feasible in low-resource settings.
97 persistent coughers with at least 5 coughs/h were monitored for >20h a day for 30 days in real world environments using Hyfe - 2/3rds of them do not cough like metronomes
This is the first report demonstrating the feasibility of continual cough monitoring to assess the clinical impact of bronchiectasis therapy. The average rate of cough decreased significantly in all patients, suggesting that the airway clearance protocol at National Jewish is effective in rapidly reducing coughing.
Over the 477 hours monitored, 4102 cough-seconds were recorded from the 20 subjects; the CoughMonitor detected 3715 of these (overall sensitivity 90.57%) and had 520 false positives (overall false positive rate of 1.09 false positives per hour).
Continuous passive cough monitoring demonstrates the heterogeneous and stochastic pattern of persistent cough and that 24 hour counts often inaccurately reflect longer term cough rates.
In this pilot study, we were able to collect coughs in the course of routine patient workflows and demonstrate that AI enabled algorithms are predictive of which individuals are likely to have an abnormal CXR.
Chronic bronchitis (CB) is defined by a chronic cough lasting > 3 months in a year for 2 successive years without another cause. The pathology of CB involves enlargement and hypertrophy of submucosal mucus glands, increased numbers ofgoblet cells, and increased airways inflammation. Current therapies for the prominent cough are largely ineffective for many patients. ARINA-1 is a buffered fixed dose combination therapy of ascorbic acid and reduced glutathione that is nebulized twice daily via an Investigational PARI eFlow nebulizer. In addition to CB, it is currently being evaluated in non-CFbronchiectasis and lung transplantation. Studies have shown that ARINA-1 improves mucociliary clearance superior tohypertonic saline and downregulates inflammatory signaling. Thus, ARINA-1 may improve quality of life in CB by enabling mucus clearance and decreasing inflammatory signaling.
This study was an open-label pilot study of ARINA-1 in six optimally treated adult participants with a primary diagnosis of CB, an FEV1 > 50% predicted, and a summary score of>15 points on the Ease of Cough and Sputum Questionnaire (MCQ). Participants were excluded if they were current smokers or had an active exacerbation. Enrolled participants used ARINA-1 twice daily for 28 days and were followed foran additional 28 days off therapy. A wearable cough monitor (Hyfe, Wilmington, DE) was worn during a 7-day run in, 28-day treatment, and 14-day follow-up period. The MCQ and Chronic Airways Assessment Test (CAAT) were administered at baseline, day 28, and day 56. Safety, including spirometry, was monitored throughout the study. Participants improved theMQC (-5.00 ± 1.1, mean ± SD) and CAAT (-8.67 ± 5.13) at 28 days with all participants improving scores > than the minimal clinically important difference (MCID; -2 points for each questionnaire). On day 56, the MCQ scores returned to baseline (-1.17 ± 2.23). The CAAT scores on day 56 remained in the MCID range (-4.17 ± 2.32). A daily diary showed an improved sensation of mucus clearance from the first dose of ARINA-1 in all participants.
There were no changes in lung function, but cough count decreased by >30% in 6/6 subjects. A single participant requested and was given an antibiotic for7 days in week 2. Overall, ARINA-1 demonstrated a strong safety profile in patients with CB and improved quality of life and decreased cough frequency. These data demonstrate the need for further study of the use of ARINA-1 in CB
At CHEST 2025, held in Chicago, Illinois, Laurie Slovarp, PhD, CCC-SLP, professor at the University of Montana and certified speech pathologist, presented a poster on the development of a digital therapeutic designed to improve access to behavioral cough suppression therapy for patients with refractory chronic cough.
A large-scale trial examining the effect of azithromycin on the relationship between oesophageal function and cough as evaluated by Hyfe's cough monitoring technology in respiratory disease is feasible and acceptable to patients.
This study used Hyfe's wearable cough monitor during a 7-day run in, 28-day treatment, and 14-day follow-up period in patients with chronic bronchitis.
Periods of intense coughing (termed bouts, epochs or bursts) are particularly problematic for some coughers and may not be reflected by simply counting the number of coughs per day. This study explored how varying the definition of bouts yield different impressions of cough severity.